Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Literature
1.
Li X, Yuan FL, Lu WG, Zhao YQ, Li CW, Li JP, Xu RS (2010) The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 397(2):131–135PubMedCrossRef
2.
Singh AK, Misra R, Aggarwal A (2011) Th-17 associated cytokines in patients with reactive arthritis/undifferentiated spondyloarthropathy. Clin Rheumatol 30(6):771–776PubMedCrossRef
3.
Melis L, Vandooren B, Kruithof E, Jacques P, De Vos M, Mielants H, Verbruggen G, De Keyser F, Elewaut D (2010) Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 69(3):618–623PubMedCrossRef
4.
Rasmussen TK, Andersen T, Hvid M, Hetland ML, Horslev-Petersen K, Stengaard-Pedersen K, Holm CK, Deleuran B (2010) Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 37(10):2014–2020PubMedCrossRef
5.
Migita K, Koga T, Torigoshi T, Motokawa S, Maeda Y, Jiuchi Y, Izumi Y, Miyashita T, Nakamura M, Komori A, Ishibashi H (2010) Induction of interleukin-23 p19 by serum amyloid A (SAA) in rheumatoid synoviocytes. Clin Exp Immunol 162(2):244–250PubMedCrossRef
6.
Stamp LK, Easson A, Pettersson L, Highton J, Hessian PA (2009) Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis. J Rheumatol 36(11):2403–2408PubMedCrossRef
7.
Hillyer P, Larche MJ, Bowman EP, McClanahan TK, de Waal Malefyt R, Schewitz LP, Giddins G, Feldmann M, Kastelein RA, Brennan FM (2009) Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford) 48(12):1581–1589CrossRef
8.
Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, Kotake S (2007) IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9(5):R96PubMedCrossRef
9.
Paradowska-Gorycka A, Grzybowska-Kowalczyk A, Wojtecka-Lukasik E, Maslinski S (2010) IL-23 in the pathogenesis of rheumatoid arthritis. Scand J Immunol 71(3):134–145PubMedCrossRef
Metadata
Title
Emerging role of IL-23 in rheumatoid arthritis
Authors
Feng-Lai Yuan
Xia Li
Jun-Ming Sun
Rui-sheng Xu
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 8/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1801-7

Other articles of this Issue 8/2011

Clinical Rheumatology 8/2011 Go to the issue

Case Based Review

Is anti-TNF switching in refractory Still’s disease safe and effective?

Review Article

The association of Raynaud’s syndrome with rheumatoid arthritis—a meta-analysis

Original Article

How confident are internal medicine residents in rheumatology versus other common internal medicine clinical skills: an issue of training time or exposure?

Original Article

The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study

Original Article

Association and frequency of HLA-A, B and HLA-DR genes in south Tunisian patients with spondyloarthritis (SpA)

Case Based Review

Subcutaneous sarcoidosis: report of two cases and review of the literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits